太龙药业
(600222)
| 流通市值：37.20亿 | | | 总市值：37.20亿 |
| 流通股本：5.59亿 | | | 总股本：5.59亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 738,044,648.29 | 350,227,659.49 | 1,757,789,761.61 | 1,186,902,173.45 |
| 营业收入 | 738,044,648.29 | 350,227,659.49 | 1,757,789,761.61 | 1,186,902,173.45 |
| 二、营业总成本 | 731,562,312.73 | 347,500,662.61 | 1,661,897,397.98 | 1,166,973,867.61 |
| 营业成本 | 563,976,250.48 | 258,407,560.19 | 1,265,562,896.42 | 898,602,991.6 |
| 税金及附加 | 4,811,454.64 | 2,021,226.51 | 11,743,992.3 | 7,183,336.61 |
| 销售费用 | 52,833,096.14 | 28,507,487.59 | 131,209,869.93 | 88,350,750.53 |
| 管理费用 | 57,895,980.78 | 26,863,485.72 | 127,146,579.21 | 90,572,686.68 |
| 研发费用 | 23,873,898.59 | 16,858,349.35 | 67,781,719.4 | 38,101,656.16 |
| 财务费用 | 28,171,632.1 | 14,842,553.25 | 58,452,340.72 | 44,162,446.03 |
| 其中:利息费用 | 26,243,377.88 | 13,977,369.47 | 53,679,223.71 | 41,362,818.25 |
| 其中:利息收入 | 321,616.11 | 275,028.5 | 1,635,774.15 | 383,871.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,595,884.71 | 3,517,044.53 | 1,399,054.4 | 1,460,156.52 |
| 加:投资收益 | -2,958,840.33 | -1,791,188.35 | -154,766.82 | -265,270 |
| 资产处置收益 | - | - | -23,974 | 0 |
| 资产减值损失(新) | -2,106,521.39 | -2,057,358.84 | -5,615,222.38 | -178,218.88 |
| 信用减值损失(新) | 3,425,814.6 | -1,912,562.26 | -22,274,173.85 | 7,520,499.26 |
| 其他收益 | 3,002,170.52 | 2,013,705.47 | 8,485,392.52 | 6,071,247.72 |
| 四、营业利润 | 16,440,843.67 | 2,496,637.43 | 77,708,673.5 | 34,536,720.46 |
| 加:营业外收入 | 1,463.41 | 689.04 | 185,926.51 | 40,204.12 |
| 减:营业外支出 | 4,161.16 | 50 | 388,992.61 | 276,430.25 |
| 五、利润总额 | 16,438,145.92 | 2,497,276.47 | 77,505,607.4 | 34,300,494.33 |
| 减:所得税费用 | 3,277,408.11 | 182,070.01 | 11,638,041.85 | 3,825,858.26 |
| 六、净利润 | 13,160,737.81 | 2,315,206.46 | 65,867,565.55 | 30,474,636.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 13,160,737.81 | 2,315,206.46 | 65,867,565.55 | 30,474,636.07 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,032,683.58 | 2,601,166.28 | 59,996,148.47 | 25,325,461.25 |
| 少数股东损益 | 1,128,054.23 | -285,959.82 | 5,871,417.08 | 5,149,174.82 |
| 扣除非经常损益后的净利润 | 5,310,743.97 | 76,215.78 | 51,457,233.71 | 20,730,758.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0 | 0.11 | 0.05 |
| (二)稀释每股收益 | 0.02 | 0 | 0.11 | 0.05 |
| 八、其他综合收益 | -3,316,125 | -708,426.44 | -13,818,275.06 | -20,228,871.94 |
| 归属于母公司股东的其他综合收益 | -3,316,125 | -708,426.44 | -13,818,275.06 | -20,228,871.94 |
| 九、综合收益总额 | 9,844,612.81 | 1,606,780.02 | 52,049,290.49 | 10,245,764.13 |
| 归属于母公司股东的综合收益总额 | 8,716,558.58 | 1,892,739.84 | 46,177,873.41 | 5,096,589.31 |
| 归属于少数股东的综合收益总额 | 1,128,054.23 | -285,959.82 | 5,871,417.08 | 5,149,174.82 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-15 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |